Ken Walder

Prof. Ken Walder


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
KBKiymet Bozaoglu
Kiymet Bozaoglu
DSDavid Segal
David Segal
KSKatherine A. Shields
Katherine A. Shields
NCNik Cummings
Nik Cummings
JCJoanne E. Curran
Joanne E. Curran
JJJeremy B.M. Jowett
Jeremy B.M. Jowett
Context: Chemerin is a novel adipokine previously associated with metabolic syndrome phenotypes in a small sample of subjects from Mauritius. Objective: The aim of the study was to determine whether plasma chemerin levels were associated with metabolic syndrome phenotypes in a larger sample from a second, unrelated human population. Design, Setting, Patients, and Intervention: Plasma samples were obtained from the San Antonio Family Heart Study (SAFHS), a large family-based genetic epidemiological study including 1431 Mexican-American individuals. Individuals were randomly sampled without regard to phenotype or disease status. This sample is well-characterized for a variety of phenotypes related to the metabolic syndrome. Main Outcomes: Plasma chemerin levels were measured by sandwich ELISA. Linear regression and correlation analyses were used to determine associations between plasma chemerin levels and metabolic syndrome phenotypes. Results: Circulating chemerin levels were significantly higher in nondiabetic subjects with body mass index (BMI) greater than 30 kg/m2 compared with those with a BMI below 25 kg/m2 (P < 0.0001). Plasma chemerin levels were significantly associated with metabolic syndrome-related parameters, including BMI (P < 0.0001), fasting serum insulin (P < 0.0001), triglycerides (P < 0.0001), and high-density lipoprotein cholesterol (P = 0.00014), independent of age and sex in nondiabetic subjects. Conclusion: Circulating chemerin levels were associated with metabolic syndrome phenotypes in a second, unrelated human population. This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome.

1 June 2002 in Diabetes
Verified
Journal Article
Closed access
PDF file
KWKen Walder
Ken Walder
LKLakshmi Kantham
Lakshmi Kantham
JMJanine S. McMillan
Janine S. McMillan
JTJames Trevaskis
James Trevaskis
LKLyndal Kerr
Lyndal Kerr
GCGreg R. Collier
Greg R. Collier
Here we describe a novel protein, which we have named Tanis, that is implicated in type 2 diabetes and inflammation. In Psammomys obesus, a unique polygenic animal model of type 2 diabetes and the metabolic syndrome, Tanis is expressed in the liver in inverse proportion to circulating glucose (P = 0.010) and insulin levels (P = 0.004) and in direct proportion with plasma triglyceride concentrations (P = 0.007). Hepatic Tanis gene expression was markedly increased (3.1-fold) after a 24-h fast in diabetic but not in nondiabetic P. obesus. In addition, glucose inhibited Tanis gene expression in cultured hepatocytes (P = 0.006) as well as in several other cell types (P = 0.001–0.011). Thus, Tanis seems to be regulated by glucose and is dysregulated in the diabetic state. Yeast-2 hybrid screening identified serum amyloid A (SAA), an acute-phase inflammatory response protein, as an interacting protein of Tanis, and this was confirmed by Biacore experiments. SAA and other acute-phase proteins have been the focus of recent attention as risk factors for cardiovascular disease, and we contend that Tanis and its interaction with SAA may provide a mechanistic link among type 2 diabetes, inflammation, and cardiovascular disease.

24 February 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
KWKen Walder
Ken Walder
LKL. Kerr-Bayles
L. Kerr-Bayles
ACA. Civitarese
A. Civitarese
JJJ. Jowett
J. Jowett
JCJ. Curran
J. Curran
GCG. R. Collier
G. R. Collier

1 January 2000 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
KWKen Walder
Ken Walder
RFRichard P. Fahey
Richard P. Fahey
GMGreg J. Morton
Greg J. Morton
PZPaul Z. Zimmet
Paul Z. Zimmet
GCGreg R. Collier
Greg R. Collier
Psammomys obesus (the Israeli sand rat) has been well studied as an animal model of Type 2 diabetes. However, obesity phenotypes in these animals have not been fully characterized. We analyzed phenotypic data including body weight, percentage body fat, blood glucose and plasma insulin concentration for over 600 animals from the Psammomys obesus colony at Deakin University to investigate the relationships between body fat, body weight and Type 2 diabetes using regression analysis and general linear modelling. The body weight distribution in Psammomys obesus approximates a normal distribution and closely resembles that observed in human populations. Animals above the 75th percentile for body weight had increased body fat content and a greater risk of developing diabetes. Increased visceral fat content .was also associated with elevated blood glucose and plasma insulin concentrations in these animals. A familial effect was also demonstrated in Psammomys obesus, and accounted for 51% of the variation in body weight, and 23–26% of the variation in blood glucose and plasma insulin concentrations in these animals. Psammomys obesus represents an excellent animal model of.obesity and Type 2 diabetes that exhibits a phenotypic pattern closely resembling that observed in human population studies. The obesity described in these animals was familial in nature and was significantly associated with Type 2 diabetes.

28 March 2002 in International Journal of Obesity
Verified
Journal Article
Closed access
KWKen Walder
Ken Walder
JMJ McMillan
J McMillan
NLN Lapsys
N Lapsys
AKA Kriketos
A Kriketos
JTJ Trevaskis
J Trevaskis
GCG Collier
G Collier

1 April 2000 in International Journal of Obesity
Verified
Journal Article
Closed access
KWKen Walder
Ken Walder
CMC Morris
C Morris
ERE Ravussin
E Ravussin